Extract
Obstructive sleep apnoea (OSA) is characterised by repeated closure of the upper airway during sleep [1]. These apnoeic events are associated with intermittent hypoxia and hypercapnia, arousal, exaggerated negative intrathoracic pressure, and increased sympathetic output [1]. In the long term, OSA has been linked to a number of adverse metabolic, neurological, cardiovascular and malignant outcomes [2–5]. These include, but are not limited to, hypertension, atherosclerosis, diabetes mellitus, obesity, mood disorders and Alzheimer's disease. In regards to hypertension, OSA accounts for ∼35% of primary hypertension, and ∼75% of patients with treatment-resistant hypertension also have OSA [6].
Abstract
Obstructive sleep apnoea (OSA) disrupts the gut microbiota, contributing to adverse cardiovascular effects. Clinical research on patients' gut microbiota may help in finding treatments preventing OSA-associated cardiovascular outcomes. https://bit.ly/3TygLl4
Footnotes
Conflict of interest: The authors have nothing to disclose.
- Received October 11, 2022.
- Accepted October 13, 2022.
- Copyright ©The authors 2023. For reproduction rights and permissions contact permissions{at}ersnet.org